Bestatin, a chemically defined immunostimulant of low molecular weight, suppressed the gradually-occurring lymph node metastasis of P388 leukemia in CDFI mice when administered i.p. at the doses of I -30 jig/mouse. It could not, however, suppress the established large metastasis of P388 leukemia. Lymph node cells isolated from the mice given bestatin i.p. at 1 and 30 leg/mouse showed stronger cytostatic activity against P388 leukemic cells in vitro than those from the untreated mice.
Bestatin, a dipeptide [(2S, 3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-leucine,
is a low toxicity immunostimulant recently developed by UMEZAWA et al. 1, 2) . It binds to the cell surface of lymphocytes and macrophages'2~4) and enhances both humoral and cell-mediated immune functions'1,2,5~7). Bestatin possesses antitumor activity and also enhances the antitumor activity of bleomycin and adriamycine6.
In the present study, we examined the inhibitory effect of bestatin on lymph node metastasis of P388 leukemia, In an experimental model of lymph node metastasis using P388 leukemia, the tumor cells metastasize primarily from the inoculation site to the axillary lymph node8). Bestatin could suppress the micrometastasis of tumor cells occurring gradually, but it could not suppress the established large lymph node metastasis.
Materials and Methods
Animals and Tumor Adult female CDF, mice (Charles River Japan Inc., Tokyo, Japan) weighing 20 -23 g were used in all experiments; DBA/2Cr mice (Simonsen Laboratories Inc., Gilroy Calif., U.S.A.) were the P388 leukemia carriers.
P388 leukemia cells were supplied by the Mason Research Institute, Worcester, Mass., U.S.A., under the auspices of the National Cancer Institute, NIH, Bethesda, Md., U.S.A.
Bestatin
Bestatin was provided by Dr. H. UMEZAWA, Institute of Microbial Chemistry, Shinagawa, Tokyo, Japan.
Evaluation of Antitumor Activity P388 leukemic cells (1 x 106) suspended in one-tenth nil of HANKS' balanced salt solution was inoculated i.p. into CDF, mice. Bestatin was dissolved in 0.15 M NaCl and administered i.p. on days 1 "9. The control animals received the vehicle. Antitumor activity was determined by comparing the mean survival time of treated groups (T) with that of control groups (C) and expressed as a percentage (T/C %).
Inhibition of Lymph Node Metastasis
Experimental model system of lymph node metastasis of P388 leukemia was used'). Briefly, P388 leukemic cells (3 x 105) were suspended in 0.05 ml HANKS' balanced salt solution and inoculated s.c. into the right forefootpad of CDF, mice. As reported previously'8, P388 leukemic cells metastasized primarily to the right axillary lymph node. Bestatin was administered i.p. at I -30 /sg/mouse daily for 1 -11 days. The control animals received the vehicle (0.15 M NaCl). Fifteen mice were used per dosage. Twelve days after tumor inoculation, the mice were killed and the axillary lymph node was removed. The extent of metastasis in the axillary lymph node was estimated by the bioassay method, where the whole axillary lymph node with tumor metastasis was transferred i.p. to normal mice under aseptic conditions. Antimetastatic activity was also expressed by T/C values calculated on the basis of the mean survival time of treated to control animals. Alternatively, the number of P388 cells in the axillary lymph node was calculated by the survival time of lymph node recipient mice.
In another experiment, I x 106 P388 leukemic cells were inoculated, and the right forelimb including the original tumor was amputated on day 6 when the metastasis had already been established. Bestatin was given i.p. at I -90 ug/mouse daily 4 times starting from day 8. On day 12, the axillarly lymph node was transferred i.p. to normal mice to estimate the antimetastatic activity of bestatin as described above.
In Vitro Growth Inhibition Assay Lymph node cells were assayed for in vitro P388 growth inhibition according to the method described previously9). Axillary lymph nodes were removed from mice (10 mice per group) which was given bestatin i.p. at 1 /cg and 30 pg/mouse daily for II days. Lymph node was squeezed gently with forceps to release cells into RPMI medium 1640 (Grand Island Biological Co., Grand Island, N.Y., U.S.A.) containing 10% fetal bovine serum (Grand Island Biological), 20 /6M 2-mercaptoethanol and kanamycin at 100 ug/ml10). A free cell suspension was prepared by pipetting and the cell suspension was filtered through 4 folds of gauze. The cells were collected by centrifugation at 70 x g for 5 minutes.
The cells (0.3 -1.0 x 108) from lymph node were incubated in I ml of the culture medium at 37°C in a humidified atomosphere with 5 % CO, in a Falcon 2054 tube. After 24 hours, I ml of the medium containing 2 x 103 P388 cells was added to the medium and P388 cells were cultivated at 37°C10>. On day 3, an aliquot (50 /61) of cell suspension was transferred into fresh culture medium and P388 cells were cultivated for another 3 days. P388 cells were then counted with a Coulter counter10). The growth inhibition was expressed as relative percentage of P388 cell numbers in test and control experiments.
Results

Antitumor Activity of Bestatin
Bestatin administered i.p. daily for 9 days did not show any significant antitumor activity against i.p. inoculated P388 leukemia (Table 1 ). This indicates that bestatin is not a cytotoxic agent against P388 leukemia. Table 1 . Effect of bestatin on the survival time of mice bearing P388 leukemia. Table 3 . Effect of bestatin on the established lymph node metastasis of P388 leukemia. 
Inhibition of Lymph Node Metastasis by Bestatin
Bestatin, when administered i.p. at I -30 ieg/mouse daily for 11 days, efficiently inhibited the lymph node metastasis of P388 leukemia ( Table 2 ). The most prominent effect was observed at a dose of I fsg/ mouse, where the number of the metastatic cells in axillary lymph node was diminished by more than 99.7 %. In these experiment, metastasis occurs time-dependently and bestatin was given daily for 11 days.
Bestatin administered i.p. daily for 4 days could not suppress the established tumor-metastasis of P388 leukemia (Table 3) cells. In in vivo experiment, bestatin efficiently inhibited the metastasis of P388 leukemia when the antibiotic was administered continuously after tumor inoculation. In this model system, P388 cells inoculated into the forefootpad metastasized to the axillary lymph node time-dependently8). We assumed that enough effector cells in the lymph node could attack the small number of P388 cells which were continuously transported from the inoculation site to the axillary lymph node. It has been difficult for non-specific immunomodulator, such as bestatin, to suppress large tumor metastasis. Bestatin could not suppress the established large metastases of P388 leukemia. However, it may be able to inhibit a micrometastasis or metastases which are just occurring by immune mechanisms. 
